Skip to main content
Top
Published in: Malaria Journal 1/2013

Open Access 01-12-2013 | Research

Biological evaluation of hydroxynaphthoquinones as anti-malarials

Authors: Desiree C Schuck, Sabrina B Ferreira, Laura N Cruz, David R da Rocha, Miriam S Moraes, Myna Nakabashi, Philip J Rosenthal, Vitor F Ferreira, Celia RS Garcia

Published in: Malaria Journal | Issue 1/2013

Login to get access

Abstract

Background

The hydroxynaphthoquinones have been extensively investigated over the past 50 years for their anti-malarial activity. One member of this class, atovaquone, is combined with proguanil in Malarone®, an important drug for the treatment and prevention of malaria.

Methods

Anti-malarial activity was assessed in vitro for a series of 3-alkyl-2-hydroxy-1,4-naphthoquinones (N1-N5) evaluating the parasitaemia after 48 hours of incubation. Potential cytotoxicity in HEK293T cells was assessed using the MTT assay. Changes in mitochondrial membrane potential of Plasmodium were measured using the fluorescent dye Mitrotracker Red CMXROS.

Results

Four compounds demonstrated IC50s in the mid-micromolar range, and the most active compound, N3, had an IC50 of 443 nM. N3 disrupted mitochondrial membrane potential, and after 1 hour presented an IC50ΔΨmit of 16 μM. In an in vitro cytotoxicity assay using HEK 293T cells N3 demonstrated no cytotoxicity at concentrations up to 16 μM.

Conclusions

N3 was a potent inhibitor of mitochondrial electron transport, had nanomolar activity against cultured Plasmodium falciparum and showed minimal cytotoxicity. N3 may serve as a starting point for the design of new hydroxynaphthoquinone anti-malarials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gazarini ML, Sigolo CA, Markus RP, Thomas AP, Garcia CR: Antimalarial drugs disrupt ion homeostasis in malarial parasites. Mem Inst Oswaldo Cruz. 2007, 102: 329-334. 10.1590/S0074-02762007000300012.CrossRefPubMed Gazarini ML, Sigolo CA, Markus RP, Thomas AP, Garcia CR: Antimalarial drugs disrupt ion homeostasis in malarial parasites. Mem Inst Oswaldo Cruz. 2007, 102: 329-334. 10.1590/S0074-02762007000300012.CrossRefPubMed
2.
go back to reference Garcia CR, de Azevedo MF, Wunderlich G, Budu A, Young JA, Bannister L: Plasmodium in the postgenomic era: new insights into the molecular cell biology of malaria parasites. Int Rev Cell Mol Biol. 2008, 266: 85-156.CrossRefPubMed Garcia CR, de Azevedo MF, Wunderlich G, Budu A, Young JA, Bannister L: Plasmodium in the postgenomic era: new insights into the molecular cell biology of malaria parasites. Int Rev Cell Mol Biol. 2008, 266: 85-156.CrossRefPubMed
3.
go back to reference Schlitzer M: Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem. 2007, 2: 944-986.CrossRefPubMed Schlitzer M: Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem Med Chem. 2007, 2: 944-986.CrossRefPubMed
4.
go back to reference WHO: World Malaria Report. 2010, Geneva: World Health Organization WHO: World Malaria Report. 2010, Geneva: World Health Organization
5.
go back to reference Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997, 272: 3961-3966. 10.1074/jbc.272.7.3961.CrossRefPubMed Srivastava IK, Rottenberg H, Vaidya AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J Biol Chem. 1997, 272: 3961-3966. 10.1074/jbc.272.7.3961.CrossRefPubMed
6.
go back to reference Hooker SC: Lomatiol. II. Its occurrence, constitution, relation to and conversion into lapachol. Also a synthesis of lapachol. J Am Chem Soc. 1936, 58: 1181-1190. 10.1021/ja01298a032.CrossRef Hooker SC: Lomatiol. II. Its occurrence, constitution, relation to and conversion into lapachol. Also a synthesis of lapachol. J Am Chem Soc. 1936, 58: 1181-1190. 10.1021/ja01298a032.CrossRef
7.
go back to reference Fieser LF, Berliner E, Bondhus FJ, Chang FC, Dauben WG, Ettlinger MG, Fields GFM, Fieser M, Heidelberger C, Heymann H, Seligman AM, Vaughan WR, Wilson AG, Wilson E, Wu M, Leffler MT, Hamlin KE, Hathaway RJ, Matson EJ, Moore EE, Moore MB, Rapala RT, Zaugg HE: Naphthoquinone antimalarials.4.5.6.7.8.9.10.11. synthesis. J Am Chem Soc. 1948, 70: 3174-3215. 10.1021/ja01190a004.CrossRefPubMed Fieser LF, Berliner E, Bondhus FJ, Chang FC, Dauben WG, Ettlinger MG, Fields GFM, Fieser M, Heidelberger C, Heymann H, Seligman AM, Vaughan WR, Wilson AG, Wilson E, Wu M, Leffler MT, Hamlin KE, Hathaway RJ, Matson EJ, Moore EE, Moore MB, Rapala RT, Zaugg HE: Naphthoquinone antimalarials.4.5.6.7.8.9.10.11. synthesis. J Am Chem Soc. 1948, 70: 3174-3215. 10.1021/ja01190a004.CrossRefPubMed
8.
go back to reference Barton V, Fisher N, Biagini GA, Ward SA, O’Neill PM: Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr Opin Chem Biol. 2010, 14: 440-446. 10.1016/j.cbpa.2010.05.005.CrossRefPubMed Barton V, Fisher N, Biagini GA, Ward SA, O’Neill PM: Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr Opin Chem Biol. 2010, 14: 440-446. 10.1016/j.cbpa.2010.05.005.CrossRefPubMed
10.
go back to reference Dressman JB, Reppas C: In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000, 11 (Suppl 2): S73-S80.CrossRefPubMed Dressman JB, Reppas C: In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur J Pharm Sci. 2000, 11 (Suppl 2): S73-S80.CrossRefPubMed
11.
go back to reference Danoun S, Baziard-Mouysset G, Stigliani J, Ane-Margail M, Payard M, Leger J, Canron X, Vial H, Loiseau P, Bories C, Recoche C: Synthesis and protozoocidal activity of new 1,4-naphthoquinones. Heterocycl Comm. 1999, 5: 343-348.CrossRef Danoun S, Baziard-Mouysset G, Stigliani J, Ane-Margail M, Payard M, Leger J, Canron X, Vial H, Loiseau P, Bories C, Recoche C: Synthesis and protozoocidal activity of new 1,4-naphthoquinones. Heterocycl Comm. 1999, 5: 343-348.CrossRef
12.
go back to reference El Hage S, Ane M, Stigliani J, Marjorie M, Vial H, Baziard-Mouysset G, Payard M: Synthesis and antimalarial activity of new atovaquone derivatives. Eur J Med Chem. 2009, 44: 4778-4782. 10.1016/j.ejmech.2009.07.021.CrossRefPubMed El Hage S, Ane M, Stigliani J, Marjorie M, Vial H, Baziard-Mouysset G, Payard M: Synthesis and antimalarial activity of new atovaquone derivatives. Eur J Med Chem. 2009, 44: 4778-4782. 10.1016/j.ejmech.2009.07.021.CrossRefPubMed
13.
go back to reference Hughes L, Lanteri C, O’Neil M, Johnson J, Gribble G, Trumpower B: Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance. Mol Biochem Parasitol. 2011, 177: 12-19. 10.1016/j.molbiopara.2011.01.002.CrossRefPubMed Hughes L, Lanteri C, O’Neil M, Johnson J, Gribble G, Trumpower B: Design of anti-parasitic and anti-fungal hydroxy-naphthoquinones that are less susceptible to drug resistance. Mol Biochem Parasitol. 2011, 177: 12-19. 10.1016/j.molbiopara.2011.01.002.CrossRefPubMed
14.
go back to reference Hughes L, Covian R, Gribble G, Trumpower B: Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones. Biochim Biophys Acta. 2010, 1797: 38-43.PubMedCentralCrossRefPubMed Hughes L, Covian R, Gribble G, Trumpower B: Probing binding determinants in center P of the cytochrome bc(1) complex using novel hydroxy-naphthoquinones. Biochim Biophys Acta. 2010, 1797: 38-43.PubMedCentralCrossRefPubMed
15.
go back to reference Ferreira S, da Rocha D, Carneiro J, Santos W, Ferreira V: A new method to prepare 3-Alkyl-2-hydroxy-1,4-naphthoquinones: synthesis of lapachol and phthiocol. Synlett. 2011, 2011: 1551-1554. 10.1055/s-0030-1260771.CrossRef Ferreira S, da Rocha D, Carneiro J, Santos W, Ferreira V: A new method to prepare 3-Alkyl-2-hydroxy-1,4-naphthoquinones: synthesis of lapachol and phthiocol. Synlett. 2011, 2011: 1551-1554. 10.1055/s-0030-1260771.CrossRef
16.
go back to reference Trager W, Jensen J: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.CrossRefPubMed Trager W, Jensen J: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.CrossRefPubMed
17.
go back to reference Lambros C, Vanderberg J: Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979, 65: 418-420. 10.2307/3280287.CrossRefPubMed Lambros C, Vanderberg J: Synchronization of Plasmodium falciparum erythrocytic stages in culture. J Parasitol. 1979, 65: 418-420. 10.2307/3280287.CrossRefPubMed
18.
go back to reference Jogdand PS, Singh SK, Christiansen M, Dziegiel MH, Singh S, Theisen M: Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition. Malar J. 2012, 11: 235-10.1186/1475-2875-11-235.PubMedCentralCrossRefPubMed Jogdand PS, Singh SK, Christiansen M, Dziegiel MH, Singh S, Theisen M: Flow cytometric readout based on Mitotracker Red CMXRos staining of live asexual blood stage malarial parasites reliably assesses antibody dependent cellular inhibition. Malar J. 2012, 11: 235-10.1186/1475-2875-11-235.PubMedCentralCrossRefPubMed
19.
go back to reference Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47: 936-942.PubMed Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987, 47: 936-942.PubMed
20.
go back to reference Kessl JJ, Meshnick SR, Trumpower BL: Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol. 2007, 23: 494-501. 10.1016/j.pt.2007.08.004.CrossRefPubMed Kessl JJ, Meshnick SR, Trumpower BL: Modeling the molecular basis of atovaquone resistance in parasites and pathogenic fungi. Trends Parasitol. 2007, 23: 494-501. 10.1016/j.pt.2007.08.004.CrossRefPubMed
21.
go back to reference Kongkathip N, Pradidphol N, Hasitapan K, Grigg R, Kao WC, Hunte C, Fisher N, Warman AJ, Biagini GA, Kongsaeree P, Chuawong P, Kongkathip B: Transforming rhinacanthin analogues from potent anticancer agents into potent antimalarial agents. J Med Chem. 2010, 53: 1211-1221. 10.1021/jm901545z.CrossRefPubMed Kongkathip N, Pradidphol N, Hasitapan K, Grigg R, Kao WC, Hunte C, Fisher N, Warman AJ, Biagini GA, Kongsaeree P, Chuawong P, Kongkathip B: Transforming rhinacanthin analogues from potent anticancer agents into potent antimalarial agents. J Med Chem. 2010, 53: 1211-1221. 10.1021/jm901545z.CrossRefPubMed
22.
go back to reference Sharma A, Santos I, Gaur P, Ferreira V, Garcia C, Rochab D: Addition of thiols to o-quinone methide: New 2-hydroxy-3-phenylsulfanylmethyl [1,4]naphthoquinones and their activity against the human malaria parasite Plasmodium falciparum (3D7). Eur J Med Chem. 2013, 59: 48-53.CrossRefPubMed Sharma A, Santos I, Gaur P, Ferreira V, Garcia C, Rochab D: Addition of thiols to o-quinone methide: New 2-hydroxy-3-phenylsulfanylmethyl [1,4]naphthoquinones and their activity against the human malaria parasite Plasmodium falciparum (3D7). Eur J Med Chem. 2013, 59: 48-53.CrossRefPubMed
23.
go back to reference Hudson A, Randall A, Fry M, Ginger C, Hill B, Latter V, McHardy N, Williams R: Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity. Parasitology. 1985, 90: 45-55. 10.1017/S0031182000049003.CrossRefPubMed Hudson A, Randall A, Fry M, Ginger C, Hill B, Latter V, McHardy N, Williams R: Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity. Parasitology. 1985, 90: 45-55. 10.1017/S0031182000049003.CrossRefPubMed
24.
go back to reference Hammond D, Burchell J, Pudney M: Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol. 1985, 14: 97-109. 10.1016/0166-6851(85)90109-4.CrossRefPubMed Hammond D, Burchell J, Pudney M: Inhibition of pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. Mol Biochem Parasitol. 1985, 14: 97-109. 10.1016/0166-6851(85)90109-4.CrossRefPubMed
25.
go back to reference Weaver R, Dickins M, Burke M: Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. Biochem Pharmacol. 1993, 46: 1183-1197. 10.1016/0006-2952(93)90467-B.CrossRefPubMed Weaver R, Dickins M, Burke M: Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. Biochem Pharmacol. 1993, 46: 1183-1197. 10.1016/0006-2952(93)90467-B.CrossRefPubMed
26.
go back to reference Kessl JJ, Moskalev NV, Gribble GW, Nasr M, Meshnick SR, Trumpower BL: Parameters determining the relative efficacy of hydroxy-naphthoquinone inhibitors of the cytochrome bc1 complex. Biochim Biophys Acta. 2007, 1767: 319-326. 10.1016/j.bbabio.2007.02.014.PubMedCentralCrossRefPubMed Kessl JJ, Moskalev NV, Gribble GW, Nasr M, Meshnick SR, Trumpower BL: Parameters determining the relative efficacy of hydroxy-naphthoquinone inhibitors of the cytochrome bc1 complex. Biochim Biophys Acta. 2007, 1767: 319-326. 10.1016/j.bbabio.2007.02.014.PubMedCentralCrossRefPubMed
Metadata
Title
Biological evaluation of hydroxynaphthoquinones as anti-malarials
Authors
Desiree C Schuck
Sabrina B Ferreira
Laura N Cruz
David R da Rocha
Miriam S Moraes
Myna Nakabashi
Philip J Rosenthal
Vitor F Ferreira
Celia RS Garcia
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2013
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-12-234

Other articles of this Issue 1/2013

Malaria Journal 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.